NCT05709093终止3 期
A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd.44 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2023年3月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 44
- 主要终点
- Overall Survival Overall Survival(OS)
研究概览
简要总结
This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in treatment-naïve subjects with intermediate- and high-risk MDS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, ≥ 18 years of age at the time of signing the ICF.
- •Subjects with intermediate- and high-risk MDS who are confirmed by bone marrow aspiration or pathological biopsy according to the diagnostic criteria of World Health Organization (WHO) 2016 or who are eligible for blasts in bone marrow and peripheral blood < 20% and have a score > 3.5 according to the revised International Prognostic Scoring System (IPSS-R).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to
- •Subjects without any prior anti-tumor therapy for MDS, including demethylated drugs (eg, AZA, decitabine), chemotherapy, targeted therapy, or HSCT. The blood transfusion or use of hematopoietic growth factors and supplementation of hematopoietic raw materials such as folic acid, vitamin B12 are permitted. For patients who ever took lenalidomide, thalidomide, antithymocyte globulin (ATG), or ciclosporin before study entry, there should be a washout period of at least 28 days prior to the first dose.
- •Subjects who are eligible for HSCT and have no pre-scheduled HSCT at screening, or subjects who are ineligible for HSCT and have no scheduled HSCT at screening
- •Expected survival ≥ 12 weeks
- •Subjects with adequate organ function and laboratory tests meet the following requirements
- •Female subjects of childbearing potential or male subjects whose partner is a woman of childbearing potential are required to use effective contraception throughout the treatment period and until 6 months after the treatment period.
- •Subjects must be willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy before study treatment, and must be willing to undergo bone marrow aspiration and biopsy after receiving study treatment.
- •Subjects must give informed consent before starting the study and sign written ICF voluntarily by themselves (or their legal representatives). Subjects or their legal representatives should be able to communicate well with investigators and agree to adhere with the study protocol and complete the study
排除标准
- •Patients who have transformed from MDS to AML, or have been diagnosed with treatment-related MDS (t-MDS), or patients with myeloproliferative neoplasia (MPN) or myelodysplastic syndrome/myeloproliferative disorder (MDS/MPN) that meet WHO 2016 criteria
- •Previously received any anti-CD47 antibody or SIRPα antibody or the drugs targeting the same target
- •Subjects have received or plan to receive the allogeneic stem cell transplantation or organ transplantation during the study
- •History of chronic hemolytic anemia due to other diseases or clinically significant positive hemolysis-related test at screening (except positive hemolysis test due to MDS)
- •Concurrent participation in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Subjects plan to receive other anti-tumor therapies, including but not limited to chemotherapy, biotherapy and immunotherapy, while participating in the study
研究组 & 干预措施
Lemzoparlimab in combination with AZA
Experimental
干预措施: Lemzoparlimab+Azacitidine (AZA) (Drug)
AZA monotherapy
Active Comparator
干预措施: Azacitidine (AZA) (Drug)
结局指标
主要结局
Overall Survival Overall Survival(OS)
时间窗: From date of randomization until the date of first documented progression or date from any cause,whichever came first, assessed up to 50 months.
次要结局
未报告次要终点
研究者
研究点 (44)
Loading locations...
相似试验
招募中
3 期
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerUrothelial CarcinomaNCT06592326Mabwell (Shanghai) Bioscience Co., Ltd.460
已完成
3 期
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCHepatocellular CarcinomaNCT04720716Innovent Biologics (Suzhou) Co. Ltd.344
尚未招募
3 期
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionAdjuvant TherapyImmunotherapyHCCNCT04682210Sun Yat-sen University246
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155
招募中
3 期
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT04578613Beijing InnoCare Pharma Tech Co., Ltd.218